COMMUNIQUÉS West-GlobeNewswire

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
01/06/2026
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
01/06/2026
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE’s Strategic Expansion into AI Energy Infrastructure BOCA RATON, [...]
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
01/06/2026
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs [...]
Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis
01/06/2026
Renexxion plans to file new drug application (NDA) with the Food and Drug Administration (FDA) using future Phase 3 results ROSCREA, Ireland and FREIBURG, Germany, June 01, 2026 (GLOBE NEWSWIRE) -- Renexxion Ireland [...]
Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development
01/06/2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS–based proteomics for research and pharmaceutical drug development. [...]
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
01/06/2026
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal [...]
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
01/06/2026
The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision Bitopertin, an oral glycine transporter 1 ( [...]
Ardena appoints Ariane de Ganck as Chief Scientific Officer
01/06/2026
Ghent, Belgium, June 1, 2026 - Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, today announced the appointment of Ariane de Ganck, PhD, as Chief [...]
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
01/06/2026
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability in heavily [...]
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
01/06/2026
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back pain Nociscan’s underlying MRS technology enabled measurement of intradiscal propionic acid to [...]
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
01/06/2026
REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and offers for ALVO [...]
Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases
01/06/2026
HELSINKI, June 01, 2026 (GLOBE NEWSWIRE) -- Aplagon , a clinical-stage biotech developing first-in-class therapies for thromboinflammatory diseases, today announced the comprehensive publication of an invited review [...]
Human Appeal Releases “Thrive with Dignity” Impact Report, Highlighting Support for Over 7.3 Million People Globally
01/06/2026
Key 2025 Impact Highlights Include Human Appeal’s work in: Reaching 7,348,330 people through life-saving aid and long-term programs across 30 countries. Providing emergency aid to 2,761,965 people across 15 countries [...]
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
01/06/2026
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia
01/06/2026
Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia, an area with no approved pharmacologic treatments RJx-01 offers a multi-pathway approach targeting several [...]
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
01/06/2026
Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia, unlocking up to $1 [...]
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
01/06/2026
Analysis from the Phase 3 COMPETE trial suggests population-based modeling may enable accurate individualized dosimetry with substantially fewer imaging requirements Los Angeles, California, June 1, 2026 — ITM Isotope [...]
New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
01/06/2026
The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and mortality in patients with resistant hypertension. Allschwil, Switzerland – June 01, 2026 [...]
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
01/06/2026
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardiac safety LONDON [...]

Pages